CLINICAL AND PARA-CLINICAL FEATURES OF MANTLE CELL LYMPHOMA AT K HOSPITAL
Main Article Content
Abstract
Objective: Describe the clinical and paraclinical characteristics of Mantle cell lymphoma. Subjects and methods: A cross-sectional descriptive prospective study was conducted on 73 patients with mantle cell lymphoma treated with RDHAP/RCHOP or RB/RBAC regimens at the Hematologic Oncology Department, K Hospital from May 2019 to May 2024. Results: The average age was 60; The male/female ratio was ~2.17; PS 0 accounted for 87.7%. Syndrome B occurred in 27.4% of patients; Patients admitted to the hospital due to lymphadenopathy accounted for 64.4%; The median lesion size was 4.0 cm. Bulky lesions accounted for 17.8%; The most common lymph node lesions were abdominal lymph nodes (84.9%) and head and neck lymph nodes (72.6%); There were 48 patients with extranodal lesions accounting for 65.8%, of which the highest rate of lesions in the colon was 27.4% and the stomach was 24.7%; the rate of low or intermediate MIPI risk group was 32%; high risk was 36%; patients were mainly in stage 3 or 4 accounting for 86%. Conclusion: The characteristic clinical features of mantle cell lymphoma support doctors in the process of early diagnosis and timely and appropriate treatment selection for these patients.
Article Details
Keywords
Mantle cell non-Hodgkin lymphoma
References
2. Carlo Visco, Silvia Finotto, Renato Zambello et al. Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. Journal of clinical oncology. 2013:1442-1449.
3. Carlo Visco. Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL. Blood Adv. 2023:3916–3924.
4. LaCasce AS. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012:2093.
5. Linton K., Dreyling M. EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Mantle Cell Lymphoma. Hemasphere. 2020:464.
6. Olivier Hermine, Eva Hoster, Jan Walewski et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016:565-575.
7. Schulz H. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007:706.